The journal Vaccines recently published a Short Communication that presented a benefit–risk assessment for the Novavax COVID-19 protein-based vaccine (NVX-CoV2373). Published on March 16, 2024, this analysis used data on myocarditis/pericarditis cases observed in the NVX-CoV2373... READ →
Precision Vaccinations
/ March 19th, 2024Eliminating fake vaccine news with pharmacist, nurse, and physician review.
For more articles, try our search.